{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T08:27:56Z","timestamp":1769588876686,"version":"3.49.0"},"reference-count":82,"publisher":"Endocrinology Research Centre","issue":"5","license":[{"start":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T00:00:00Z","timestamp":1657497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.probl-endojournals.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":["www.probl-endojournals.ru"],"crossmark-restriction":true},"short-container-title":["Probl Endokrinol (Mosk)"],"abstract":"<jats:p>Tumor induced osteomalacia is a rare acquired disease. The cause is a mesenchymal tumor secreting fibroblast growth factor 23 (FGF23). An excessive amount of FGF 23 disrupts the metabolism of phosphorus and vitamin D, which leads to severe paraneoplastic syndrome, manifested in the form of multiple fractures, severe pain in the bones and generalized myopathy. With oncogenic osteomalacia, a complete cure is possible with radical resection of the tumor. Unfortunately, localization, small size of formations and rare frequency of occurrence lead to the fact that the disease remains unrecognized for a long time and leads to severe, disabling consequences. A step-by-step approach to diagnosis improves treatment outcomes. First, a thorough anamnesis is collected, then functional visualization is performed and the diagnosis is confirmed by anatomical visualization of the tumor. After that, the method of choice is a surgical treatment. If resection is not possible, then conservative therapy with active metabolites of vitamin D and phosphorus salts is indicated. New therapeutic approaches, such as the antibody to FGF23 or the pan-inhibitor of receptors to FGF, are actively developing. This article provides an overview of modern approaches to the diagnosis and treatment of this disease.<\/jats:p>","DOI":"10.14341\/probl13130","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T20:09:50Z","timestamp":1667851790000},"page":"56-66","update-policy":"https:\/\/doi.org\/10.14341\/crossmarkpolicy2018","source":"Crossref","is-referenced-by-count":11,"title":["FGF23 tumor induced osteomalacia"],"prefix":"10.14341","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7055-2407","authenticated-orcid":true,"given":"S. A.","family":"Gronskaia","sequence":"first","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6674-6441","authenticated-orcid":true,"given":"Zh. E.","family":"Belaya","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5634-7877","authenticated-orcid":true,"given":"G. A.","family":"Melnichenko","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5458","published-online":{"date-parts":[[2022,7,11]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most Osteomalacia-associated Mesenchymal Tumors Are a Single Histopathologic Entity. Am J Surg Pathol. 2004;28(1):1-30. doi: https:\/\/doi.org\/10.1097\/00000478-200401000-00001","DOI":"10.1097\/00000478-200401000-00001"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Florenzano P, Hartley IR, Jimenez M, et al. Tumor-Induced Osteomalacia. Calcif Tissue Int. 2021;108(1):128-142. doi: https:\/\/doi.org\/10.1007\/s00223-020-00691-6","DOI":"10.1007\/s00223-020-00691-6"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Feng J, Jiang Y, Wang O, et al. The diagnostic dilemma of tumor induced osteomalacia: a retrospective analysis of 144 cases. Endocr J. 2017;64(7):675-683. doi: https:\/\/doi.org\/10.1507\/endocrj.EJ16-0587","DOI":"10.1507\/endocrj.EJ16-0587"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Kobayashi H, Ito N, Akiyama T, et al. Prevalence and clinical outcomes of hip fractures and subchondral insufficiency fractures of the femoral head in patients with tumour-induced osteomalacia. Int Orthop. 2017;41(12):2597-2603. doi: https:\/\/doi.org\/10.1007\/s00264-017-3610-3","DOI":"10.1007\/s00264-017-3610-3"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Toro L, Barrientos V, Le\u00f3n P, et al. Erythropoietin induces bone marrow and plasma fibroblast growth factor 23 during acute kidney injury. Kidney Int. 2018;93(5):1131-1141. doi: https:\/\/doi.org\/10.1016\/j.kint.2017.11.018","DOI":"10.1016\/j.kint.2017.11.018"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Rabadi S, Udo I, Leaf DE, Waikar SS, Christov M. Acute blood loss stimulates fibroblast growth factor 23 production. Am J Physiol Physiol. 2018;314(1):F132-F139. doi: https:\/\/doi.org\/10.1152\/ajprenal.00081.2017","DOI":"10.1152\/ajprenal.00081.2017"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate Homeostasis. J Bone Miner Res. 2003;19(3):429-435. doi: https:\/\/doi.org\/10.1359\/JBMR.0301264","DOI":"10.1359\/JBMR.0301264"},{"key":"ref8","unstructured":"Novikov PV. Rakhit i nasledstvennye rakhitopodobnye zabolevaniia u detei: diagnostika, lechenie, profilaktika: monografiia. Moscow: Triada-Kh; 2006. 336 p. (In Russ.)."},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Eremkina AK, Mirnaya SS, Gorbacheva AM, et al. The case of oncogenic hypophosphatemic osteomalacia. Obesity and metabolism. 2020;17(2):220-227. doi: https:\/\/doi.org\/10.14341\/omet12472","DOI":"10.14341\/omet12472"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Gronskaia S, Melnichenko G, Rozhinskaya L, et al. A registry for patients with chronic hypoparathyroidism in Russian adults. Endocr Connect. 2020;9(7):627-636. doi: https:\/\/doi.org\/10.1530\/EC-20-0219","DOI":"10.1530\/EC-20-0219"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Lesnyak O, Gladkova E, Aleksandrov N, et al. Treatment of high fracture risk patients in routine clinical practice. Arch Osteoporos. 2020;15(1):184. doi: https:\/\/doi.org\/10.1007\/s11657-020-00851-z","DOI":"10.1007\/s11657-020-00851-z"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Lewiecki EM, Jackson A, Lake AF, et al. Bone Health TeleECHO: a Force Multiplier to Improve the Care of Skeletal Diseases in Underserved Communities. Curr Osteoporos Rep. 2019;17(6):474-482. doi: https:\/\/doi.org\/10.1007\/s11914-019-00543-9","DOI":"10.1007\/s11914-019-00543-9"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006;444(7120):770-774. doi: https:\/\/doi.org\/10.1038\/nature05315","DOI":"10.1038\/nature05315"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Grebennikova TA, Umiarova DS, Slashchuk KY, et al. Tumor-induced osteomalacia: a clinical case report. Osteoporos Bone Dis. 2019;21(4):24-28. doi: https:\/\/doi.org\/10.14341\/osteo10264","DOI":"10.14341\/osteo10264"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Tella SH, Amalou H, Wood BJ, et al. Multimodality Image-Guided Cryoablation for Inoperable Tumor-Induced Osteomalacia. J Bone Miner Res. 2017;32(11):2248-2256. doi: https:\/\/doi.org\/10.1002\/jbmr.3219","DOI":"10.1002\/jbmr.3219"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Li X, Jiang Y, Huo L, et al. Nonremission and Recurrent Tumor-Induced Osteomalacia: A Retrospective Study. J Bone Miner Res. 2020;35(3):469-477. doi: https:\/\/doi.org\/10.1002\/jbmr.3903.","DOI":"10.1002\/jbmr.3903"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Mak MP, da Costa e Silva VT, Martin RM, et al. Advanced prostate cancer as a cause of oncogenic osteomalacia: an underdiagnosed condition. Support Care Cancer. 2012;20(9):2195-2197. doi: https:\/\/doi.org\/10.1007\/s00520-012-1474-z","DOI":"10.1007\/s00520-012-1474-z"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Savva C, Adhikaree J, Madhusudan S, Chokkalingam K. Oncogenic osteomalacia and metastatic breast cancer: a case report and review of the literature. J Diabetes Metab Disord. 2019;18(1):267-272. doi: https:\/\/doi.org\/10.1007\/s40200-019-00398-y","DOI":"10.1007\/s40200-019-00398-y"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Lin H-A, Shih S-R, Tseng Y-T, et al. Ovarian Cancer-Related Hypophosphatemic Osteomalacia\u2014A Case Report. J Clin Endocrinol Metab. 2014;99(12):4403-4407. doi: https:\/\/doi.org\/10.1210\/jc.2014-2120","DOI":"10.1210\/jc.2014-2120"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Reinert RB, Bixby D, Koenig RJ. Fibroblast Growth Factor 23\u2013Induced Hypophosphatemia in Acute Leukemia. J Endocr Soc. 2018;2(5):437-443. doi: https:\/\/doi.org\/10.1210\/js.2018-00010","DOI":"10.1210\/js.2018-00010"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Chong WH, Molinolo AA, Chen CC, Collins MT. Tumor-induced osteomalacia. Endocr Relat Cancer. 2011;18(3):R53-R77. doi: https:\/\/doi.org\/10.1530\/ERC-11-0006","DOI":"10.1530\/ERC-11-0006"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Folpe AL. Phosphaturic mesenchymal tumors: A review and update. Semin Diagn Pathol. 2019;36(4):260-268. doi: https:\/\/doi.org\/10.1053\/j.semdp.2019.07.002","DOI":"10.1053\/j.semdp.2019.07.002"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"White KE, Larsson TE, Econs MJ. The Roles of Specific Genes Implicated as Circulating Factors Involved in Normal and Disordered Phosphate Homeostasis: Frizzled Related Protein-4, Matrix Extracellular Phosphoglycoprotein, and Fibroblast Growth Factor 23. Endocr Rev. 2006;27(3):221-241. doi: https:\/\/doi.org\/10.1210\/er.2005-0019","DOI":"10.1210\/er.2005-0019"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Armelin HA. Pituitary Extracts and Steroid Hormones in the Control of 3T3 Cell Growth. Proc Natl Acad Sci. 1973;70(9):2702-2706. doi: https:\/\/doi.org\/10.1073\/pnas.70.9.2702","DOI":"10.1073\/pnas.70.9.2702"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Gospodarowicz D. Localisation of a fibroblast growth factor and its effect alone and with hydrocortisone on 3T3 cell growth. Nature. 1974;249(5453):123-127. doi: https:\/\/doi.org\/10.1038\/249123a0","DOI":"10.1038\/249123a0"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Hui Q, Jin Z, Li X, Liu C, Wang X. FGF Family: From Drug Development to Clinical Application. Int J Mol Sci. 2018;19(7):1875. doi: https:\/\/doi.org\/10.3390\/ijms19071875","DOI":"10.3390\/ijms19071875"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol. 2001;2(3):REVIEWS3005. doi: https:\/\/doi.org\/10.1186\/gb-2001-2-3-reviews3005","DOI":"10.1186\/gb-2001-2-3-reviews3005"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Billings PC, Pacifici M. Interactions of signaling proteins, growth factors and other proteins with heparan sulfate: mechanisms and mysteries. Connect Tissue Res. 2015;56(4):272-280. doi: https:\/\/doi.org\/10.3109\/03008207.2015.1045066","DOI":"10.3109\/03008207.2015.1045066"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Kim J-H, Hwang K-H, Park K-S, et al. Biological Role of Anti-aging Protein Klotho. J Lifestyle Med. 2015;5(1):1-6. doi: https:\/\/doi.org\/10.15280\/jlm.2015.5.1.1","DOI":"10.15280\/jlm.2015.5.1.1"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Comps-Agrar L, Dunshee DR, Eaton DL, Sonoda J. Unliganded fibroblast growth factor receptor 1 forms density-independent dimers. J Biol Chem. 2015;290(40):24166-24177. doi: https:\/\/doi.org\/10.1074\/jbc.M115.681395","DOI":"10.1074\/jbc.M115.681395"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Fedyanin MY, Khmelkova DN, Serebriyskaya TS, et al. \u041f\u0435\u0440\u0441\u043f\u0435\u043a\u0442\u0438\u0432\u044b \u0442\u0435\u0440\u0430\u043f\u0435\u0432\u0442\u0438\u0447\u0435\u0441\u043a\u043e\u0433\u043e \u0432\u043e\u0437\u0434\u0435\u0439\u0441\u0442\u0432\u0438\u044f \u043d\u0430 \u0441\u0438\u0433\u043d\u0430\u043b\u044c\u043d\u044b\u0439 \u043f\u0443\u0442\u044c FGFR. Adv Mol Oncol. 2015;2(1):027. doi: https:\/\/doi.org\/10.17650\/2313-805X.2015.2.1.027-038","DOI":"10.17650\/2313-805X.2015.2.1.027-038"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun. 2000;277(2):494-498. doi: https:\/\/doi.org\/10.1006\/bbrc.2000.3696","DOI":"10.1006\/bbrc.2000.3696"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"White KE, Evans WE, O\u2019Riordan JLH, et al. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000;26(3):345-348. doi: https:\/\/doi.org\/10.1038\/81664","DOI":"10.1038\/81664"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci. 2001;98(11):6500-6505. doi: https:\/\/doi.org\/10.1073\/pnas.101545198","DOI":"10.1073\/pnas.101545198"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Simpson MA, Hsu R, Keir LS, et al. Mutations in FAM20C Are Associated with Lethal Osteosclerotic Bone Dysplasia (Raine Syndrome), Highlighting a Crucial Molecule in Bone Development. Am J Hum Genet. 2007;81(5):906-912. doi: https:\/\/doi.org\/10.1086\/522240","DOI":"10.1086\/522240"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Raine J, Winter RM, Davey A, Tucker SM. Unknown syndrome: microcephaly, hypoplastic nose, exophthalmos, gum hyperplasia, cleft palate, low set ears, and osteosclerosis. J Med Genet. 1989;26(12):786-788. doi: https:\/\/doi.org\/10.1136\/jmg.26.12.786","DOI":"10.1136\/jmg.26.12.786"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Liu S, Zhou J, Tang W, et al. Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Metab. 2006;291(1):E38-E49. doi: https:\/\/doi.org\/10.1152\/ajpendo.00008.2006","DOI":"10.1152\/ajpendo.00008.2006"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Francis F, Hennig S, Korn B, et al. A gene (PEX) with homologies to endopeptidases is mutated in patients with X\u2013linked hypophosphatemic rickets. Nat Genet. 1995;11(2):130-136. doi: https:\/\/doi.org\/10.1038\/ng1095-130","DOI":"10.1038\/ng1095-130"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Lorenz-Depiereux B, Schnabel D, Tiosano D, et al. Loss-of-Function ENPP1 Mutations Cause Both Generalized Arterial Calcification of Infancy and Autosomal-Recessive Hypophosphatemic Rickets. Am J Hum Genet. 2010;86(2):267-272. doi: https:\/\/doi.org\/10.1016\/j.ajhg.2010.01.006","DOI":"10.1016\/j.ajhg.2010.01.006"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Feng JQ, Ward LM, Liu S, et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet. 2006;38(11):1310-1315. doi: https:\/\/doi.org\/10.1038\/ng1905","DOI":"10.1038\/ng1905"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Bergwitz C, J\u00fcppner H. Regulation of Phosphate Homeostasis by PTH, Vitamin D, and FGF23. Annu Rev Med. 2010;61(1):91-104. doi: https:\/\/doi.org\/10.1146\/annurev.med.051308.111339","DOI":"10.1146\/annurev.med.051308.111339"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"White KE, Evans WE, O\u2019Riordan JLH, et al. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000;26(3):345-348. doi: https:\/\/doi.org\/10.1038\/81664","DOI":"10.1038\/81664"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Edmonston D, Wolf M. FGF23 at the crossroads of phosphate, iron economy and erythropoiesis. Nat Rev Nephrol. 2020;16(1):7-19. doi: https:\/\/doi.org\/10.1038\/s41581-019-0189-5","DOI":"10.1038\/s41581-019-0189-5"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Takashi Y, Fukumoto S. Phosphate-sensing and regulatory mechanism of FGF23 production. J Endocrinol Invest. 2020;43(7):877-883. doi: https:\/\/doi.org\/10.1007\/s40618-020-01205-9","DOI":"10.1007\/s40618-020-01205-9"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Park MY, Herrmann SM, Saad A, et al. Biomarkers of Kidney Injury and Klotho in Patients with Atherosclerotic Renovascular Disease. Clin J Am Soc Nephrol. 2015;10(3):443-451. doi: https:\/\/doi.org\/10.2215\/CJN.07290714","DOI":"10.2215\/CJN.07290714"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"David V, Dai B, Martin A, et al. Calcium Regulates FGF-23 Expression in Bone. Endocrinology. 2013;154(12):4469-4482. doi: https:\/\/doi.org\/10.1210\/en.2013-1627","DOI":"10.1210\/en.2013-1627"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Lavi-Moshayoff V, Wasserman G, Meir T, et al. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Physiol. 2010;299(4):F882-F889. doi: https:\/\/doi.org\/10.1152\/ajprenal.00360.2010","DOI":"10.1152\/ajprenal.00360.2010"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Meir T, Durlacher K, Pan Z, et al. Parathyroid hormone activates the orphan nuclear receptor Nurr1 to induce FGF23 transcription. Kidney Int. 2014;86(6):1106-1115. doi: https:\/\/doi.org\/10.1038\/ki.2014.215","DOI":"10.1038\/ki.2014.215"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Xiao L, Esliger A, Hurley MM. Nuclear fibroblast growth factor 2 (FGF2) isoforms inhibit bone marrow stromal cell mineralization through FGF23\/FGFR\/MAPK in vitro. J Bone Miner Res. 2013;28(1):35-45. doi: https:\/\/doi.org\/10.1002\/jbmr.1721","DOI":"10.1002\/jbmr.1721"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Smith RC, O\u2019Bryan LM, Farrow EG, et al. Circulating \u03b1Klotho influences phosphate handling by controlling FGF23 production. J Clin Invest. 2012;122(12):4710-4715. doi: https:\/\/doi.org\/10.1172\/JCI64986","DOI":"10.1172\/JCI64986"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Ornitz DM, Itoh N. The Fibroblast Growth Factor signaling pathway. WIREs Dev Biol. 2015;4(3):215-266. doi: https:\/\/doi.org\/10.1002\/wdev.176","DOI":"10.1002\/wdev.176"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Teven CM, Farina EM, Rivas J, Reid RR. Fibroblast growth factor (FGF) signaling in development and skeletal diseases. Genes Dis. 2014;1(2):199-213. doi: https:\/\/doi.org\/10.1016\/j.gendis.2014.09.005","DOI":"10.1016\/j.gendis.2014.09.005"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Bernuy J, Gonzales GF. Metabolismo mineral \u00f3seo en pacientes con enfermedad renal cr\u00f3nica: revisi\u00f3n sobre su fisiopatolog\u00eda y morbimortalidad. Rev Peru Med Exp Salud Publica. 2015;32(2):326. doi: https:\/\/doi.org\/10.17843\/rpmesp.2015.322.1628","DOI":"10.17843\/rpmesp.2015.322.1628"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Shimada T, Kakitani M, Yamazaki Y, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004;113(4):561-568. doi: https:\/\/doi.org\/10.1172\/JCI19081","DOI":"10.1172\/JCI200419081"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Rabadi S, Udo I, Leaf DE, et al. Acute blood loss stimulates fibroblast growth factor 23 production. Am J Physiol Renal Physiol. 2018;314(1):F132-F139. doi: https:\/\/doi.org\/10.1152\/ajprenal.00081.2017","DOI":"10.1152\/ajprenal.00081.2017"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Tohyama O, Imura A, Iwano A, et al. Klotho Is a Novel \u03b2-Glucuronidase Capable of Hydrolyzing Steroid \u03b2-Glucuronides. J Biol Chem. 2004;279(11):9777-9784. doi: https:\/\/doi.org\/10.1074\/jbc.M312392200","DOI":"10.1074\/jbc.M312392200"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Ho BB, Bergwitz C. FGF23 signalling and physiology. J Mol Endocrinol. 2021;66(2):R23-R32. doi: https:\/\/doi.org\/10.1530\/JME-20-0178","DOI":"10.1530\/JME-20-0178"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Rodelo-Haad C, Santamaria R, Mu\u00f1oz-Casta\u00f1eda JR, et al. FGF23, Biomarker or Target? Toxins (Basel). 2019;11(3):175. doi: https:\/\/doi.org\/10.3390\/toxins11030175","DOI":"10.3390\/toxins11030175"},{"key":"ref59","unstructured":"Prader A, Illig R, Uehlinger E, Stalder G. [Rickets following bone tumor]. Helv Paediatr Acta. 1959;14:554-565."},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez-Cooke E, Cruz-Rojo J, Gallego C, et al. Tumor-Induced Rickets in a Child With a Central Giant Cell Granuloma: A Case Report. Pediatrics. 2015;135(6):e1518-e1523. doi: https:\/\/doi.org\/10.1542\/peds.2014-2218","DOI":"10.1542\/peds.2014-2218"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Jung G-H, Kim J-D, Cho Y, et al. A 9-month-old phosphaturic mesenchymal tumor mimicking the intractable rickets. J Pediatr Orthop B. 2010;19(1):127-132. doi: https:\/\/doi.org\/10.1097\/BPB.0b013e32832f59cb.","DOI":"10.1097\/BPB.0b013e32832f59cb"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Chong WH, Andreopoulou P, Chen CC, et al. Tumor localization and biochemical response to cure in tumor-induced osteomalacia. J Bone Miner Res. 2013;28(6):1386-1398. doi: https:\/\/doi.org\/10.1002\/jbmr.1881","DOI":"10.1002\/jbmr.1881"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Mamedova E, Kolodkina A, Vasilyev EV, et al. Successful Use of Denosumab for Life-Threatening Hypercalcemia in a Pediatric Patient with Primary Hyperparathyroidism. Horm Res Paediatr. 2020;93(4):272-278. doi: https:\/\/doi.org\/10.1159\/000510625","DOI":"10.1159\/000510625"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Crossen SS, Zambrano E, Newman B, et al. Tumor-induced Osteomalacia in a 3-Year-Old With Unresectable Central Giant Cell Lesions. J Pediatr Hematol Oncol. 2017;39(1):e21-e24. doi: https:\/\/doi.org\/10.1097\/MPH.0000000000000686","DOI":"10.1097\/MPH.0000000000000686"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Sundaram M, McCarthy EF. Oncogenic osteomalacia. Skeletal Radiol. 2000;29(3):117-24. doi: https:\/\/doi.org\/10.1007\/s002560050581","DOI":"10.1007\/s002560050581"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Mamedova E, Dimitrova D, Przhiyalkovskaya E, et al. Non-lethal Raine Syndrome in a Middle-Aged Woman Caused by a Novel FAM20C Mutation. Calcif Tissue Int. 2019;105(5):567-572. doi: https:\/\/doi.org\/10.1007\/s00223-019-00599-w","DOI":"10.1007\/s00223-019-00599-w"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Grebennikova TA, Belaia ZhE, Tsoriev TT, et al. The endocrine function of the bone tissue. Osteoporosis and Bone Diseases. 2015;18(1):28-37. (In Russ.). doi: https:\/\/doi.org\/10.14341\/osteo2015128-37","DOI":"10.14341\/osteo2015128-37"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Belaya Z, Golounina O, Nikitin A, et al. Multiple bilateral hip fractures in a patient with dyskeratosis congenita caused by a novel mutation in the PARN gene. Osteoporos Int. 2021;32(6):1227-1231. doi: https:\/\/doi.org\/10.1007\/s00198-020-05758-6","DOI":"10.1007\/s00198-020-05758-6"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Yukina M, Nuralieva N, Sorkina E, et al. Atypical progeroid syndrome (p.E262K LMNA mutation): a rare cause of short stature and osteoporosis. Endocrinol Diabetes Metab Case Reports. 2021;2021(6):1227-1231. doi: https:\/\/doi.org\/10.1530\/EDM-20-0188","DOI":"10.1530\/EDM-20-0188"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"El-Maouche D, Sadowski SM, Papadakis GZ, et al. 68Ga-DOTATATE for Tumor Localization in Tumor-Induced Osteomalacia. J Clin Endocrinol Metab. 2016;101(10):3575-3581. doi: https:\/\/doi.org\/10.1210\/jc.2016-2052","DOI":"10.1210\/jc.2016-2052"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Ito N, Shimizu Y, Suzuki H, et al. Clinical utility of systemic venous sampling of FGF23 for identifying tumours responsible for tumour-induced osteomalacia. J Intern Med. 2010;268(4):390-394. doi: https:\/\/doi.org\/10.1111\/j.1365-2796.2010.02262.x","DOI":"10.1111\/j.1365-2796.2010.02262.x"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Andreopoulou P, Dumitrescu CE, Kelly MH, et al. Selective venous catheterization for the localization of phosphaturic mesenchymal tumors. J Bone Miner Res. 2011;26(6):1295-1302. doi: https:\/\/doi.org\/10.1002\/jbmr.316","DOI":"10.1002\/jbmr.316"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Wang H, Zhong D, Liu Y, et al. Surgical Treatments of Tumor-Induced Osteomalacia Lesions in Long Bones: Seventeen Cases with More Than One Year of Follow-up. J Bone Joint Surg Am. 2015;97(13):1084-1094. doi: https:\/\/doi.org\/10.2106\/JBJS.N.01299","DOI":"10.2106\/JBJS.N.01299"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Lee JC, Su SY, Changou CA, et al. Characterization of FN1-FGFR1 and novel FN1-FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors. Mod Pathol. 2016;29(11):1335-1346. doi: https:\/\/doi.org\/10.1038\/modpathol.2016.137.","DOI":"10.1038\/modpathol.2016.137"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Carpenter TO, Imel EA, Holm IA, et al. A clinician\u2019s guide to X-linked hypophosphatemia. J Bone Miner Res. 2011;26(7):1381-1388. doi: https:\/\/doi.org\/10.1002\/jbmr.340","DOI":"10.1002\/jbmr.340"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Jan De Beur S, Miller P, Weber T, et al. OR13-1 Burosumab Improves the Biochemical, Skeletal, and Clinical Symptoms of Tumor-Induced Osteomalacia Syndrome. J Endocr Soc. 2019;3(S1):1386-1398. doi: https:\/\/doi.org\/10.1210\/js.2019-OR13-1","DOI":"10.1210\/js.2019-OR13-1"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"W\u00f6hrle S, Bonny O, Beluch N, et al. FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone. J Bone Miner Res. 2011;26(10):2486-2497. doi: https:\/\/doi.org\/10.1002\/jbmr.478","DOI":"10.1002\/jbmr.478"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"W\u00f6hrle S, Henninger C, Bonny O, et al. Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. J Bone Miner Res. 2013;28(4):899-911. doi: https:\/\/doi.org\/10.1002\/jbmr.1810","DOI":"10.1002\/jbmr.1810"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Fumarola C, Bozza N, Castelli R, et al. Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. Front Oncol. 2019;9(S1):1386-1398. doi: https:\/\/doi.org\/10.3389\/fonc.2019.00179","DOI":"10.3389\/fonc.2019.00179"},{"key":"ref80","unstructured":"Collins MT. Striking response of tumor-induced osteomalacia to the FGFR inhibitor NVP-BGJ398. In: American Society of Bone and Mineral Research annual meeting. Seattle: WA; 2015."},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Mishra SK, Kuchay MS, Sen IB, et al. Successful Management Of Tumor\u2010Induced Osteomalacia with Radiofrequency Ablation: A Case Series. JBMR Plus. 2019;3(7):116-120. doi: https:\/\/doi.org\/10.1002\/jbm4.10178","DOI":"10.1002\/jbm4.10178"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"Payne RB. Renal Tubular Reabsorption of Phosphate (TmP\/GFR): Indications and Interpretation. Ann Clin Biochem Int J Lab Med. 1998;35(2):201-206. doi: https:\/\/doi.org\/10.1177\/000456329803500203","DOI":"10.1177\/000456329803500203"}],"container-title":["Problems of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/viewFile\/13130\/10342","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T15:30:15Z","timestamp":1668439815000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/view\/13130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,11]]},"references-count":82,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,11,6]]}},"URL":"https:\/\/doi.org\/10.14341\/probl13130","relation":{},"ISSN":["2308-1430","0375-9660"],"issn-type":[{"value":"2308-1430","type":"electronic"},{"value":"0375-9660","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7,11]]}}}